Vemurafenib, a BRAF kinase inhibitor, has been shown to be effective inBRAFV600E mutation-positive malignancies, including NSCLC and melanoma, along with several case reports of Erdheim-Chester disease
Vemurafenib, a BRAF kinase inhibitor, has been shown to be effective inBRAFV600E mutation-positive malignancies, including NSCLC and melanoma, along with […]